Form 8-K · Current report
Vertex Pharmaceuticals 8-K, filed Nov 2, 2026
- Filed
- CIK
- 0000875320
- Accession no.
- 0000875320-26-000287
Summary
Vertex Pharmaceuticals reported third-quarter 2026 total revenue of $3.44 billion, up 12% year over year, and raised its full-year 2026 revenue guidance to $13.15 billion to $13.25 billion, citing CF therapies, CASGEVY, JOURNAVX, and the Crinetics Pharmaceuticals acquisition. Vertex closed the Crinetics acquisition on September 1, adding PALSONIFY for acromegaly, and said it is preparing for a povetacicept PDUFA date on November 30.
Key points
- Vertex Pharmaceuticals reported third-quarter 2026 total revenue of $3.44 billion, up 12% from the third quarter of 2025, with U.S. revenue of $2.17 billion and revenue outside the U.S. of $1.27 billion.
- Vertex raised its full-year 2026 total revenue guidance to $13.15 billion to $13.25 billion from $13.1 billion to $13.2 billion.
- Vertex closed its acquisition of Crinetics Pharmaceuticals on September 1, 2026, and recorded $10 million of PALSONIFY revenue in September 2026.
- CASGEVY third-quarter 2026 revenue was $99 million and JOURNAVX third-quarter 2026 revenue was $58 million.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 9.01Financial Statements and Exhibits
From the filing
Item 2.02. Results of Operations and Financial Condition. On November 2, 2026, Vertex Pharmaceuticals Incorporated (the "Company") issued a press release in which it reported its consolidated financial results for the three and nine months ended September 30, 2026. A copy of that press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference. The information set forth in Exhibit 99.1 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other…
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.